The abstract is read at the publisher; the summary is JClub's.
In a companion study of Blood and Marrow Transplant Clinical Trials Network 1801, gut microbiome diversity at neutrophil engraftment was not associated with 1-year non-relapse mortality (P=0.314) in 304 participants.
- Why it matters: The trial addresses whether microbiome diversity at a key transplant milestone predicts non-relapse mortality, building on prior retrospective links between low diversity and worse outcomes.
- What they did: Using 2575 longitudinal stool samples, investigators tested associations between engraftment diversity and non-relapse mortality, and compared microbiome diversity, microbial load, and domination events between Tac/MTX (n=147) and PTCy (n=157).
- The result: Lower baseline microbiome diversity predicted shorter overall survival (P=0.007), and exploratory analyses showed lower diversity and absolute microbial load in PTCy versus Tac/MTX on days 14–28, with less prevalence of Clostridium scindens and secondary bile-acid metabolism pathways.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.